In the search for alternative therapeutic targets for SCLC, the transcription factor achaete-scute homolog 1 (ASCL1) has triggered particular interest due to its role as a key regulator of neuroendocrine differentiation and its ability to drive SCLC formation [18]. The gene discussed is ASCL1; the disease is small cell lung carcinoma.